[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636995":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":41,"responsibleParty":60,"collaborators":25,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":25,"enrollmentInfo":72,"targetDuration":25,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":84,"overallStatus":87,"whyStopped":25,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Medical College of Wisconsin","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"MRD positive","ACTIVE_COMPARATOR","MRD positive patients assigned to Arm A are required to initiate maintenance therapy on this study. Maintenance therapy will be suggested by the PIs, however final choice of maintenance is at the discretion of the treating physician.",[13],"Drug: Maintenance Therapy",{"label":15,"type":10,"description":16,"interventionNames":17},"MRD negative","MRD negative patients assigned to Arm B will receive no intervention.",[18],"Other: No intervention",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Maintenance Therapy","Maintenance therapy will be suggested by the PIs, however final choice of maintenance is at the discretion of the treating physician.",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"No intervention","Patients will receive no maintenance therapy.",[15],[31],{"name":32,"affiliation":5,"role":33},"Sameem Abedin, MD","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":39,"email":40},"Medical College of Wisconsin Cancer Center Clinical Trials Office","CONTACT","866-680-0505","8900","cccto@mcw.edu",[42],{"facility":43,"status":25,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Froedtert & the Medical College of Wisconsin","Milwaukee","Wisconsin","53226","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-87.90647,43.0389,{"lat":53,"lon":52},[56,59],{"name":32,"role":37,"phone":57,"phoneExt":25,"email":58},"414-805-4600","Sabedin@mcw.edu",{"name":32,"role":33,"phone":25,"phoneExt":25,"email":25},{"type":33,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Sameem M. Abedin, MD","Associate Professor","100636995","phase-2-a-pragmatic-clinical-trial-to-prevent-relapse-for-myeloid-malignancies-with-measurable-disease-prior-to-allogeneic-transplant-100636995",false,"NCT07572929","A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant","PREeMPT","Inclusion Criteria:\n\n* Age ≥18 years at time of transplant.\n* Must have a diagnosis of a myeloid malignancy, myelodysplastic syndrome, myeloproliferative neoplasm (including primary or secondary myelofibrosis), or acute myeloid leukemia or biphenotypic acute leukemia.\n* Pre-transplant disease assessment must include at least one:\n* Immunophenotypic assessment by flow for aberrant blasts\n* NGS to identify persistence of malignant clones using a standard clinically available assay\n* PCR based measurement of prior identified mutations (if applicable)\n* Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\nNone","ALL","18 Years",{"count":73,"type":74},450,"ESTIMATED","INTERVENTIONAL",[77],"PHASE2","This is a prospective, open-label investigation to determine whether measurable residual disease (MRD) guided assignment of maintenance therapy is effective in patients with myeloid malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). Pre-HCT, patients will undergo usual disease assessments which should include immunophenotypic and\u002For molecular testing. Based on the results of these tests, patients may or may not be recommended to receive maintenance therapy post-transplant, depending on the presence or absence of a residual malignant clone.",[80,81,82,83],"Myeloid Disorders","Myelodysplastic Syndromes","Myeloproliferative Neoplasm","Acute Myeloid Leukemia",[85,86],"Allogeneic hematopoietic cell transplantation","Measurable residual disease","NOT_YET_RECRUITING","2026-06-19",{"date":90,"type":91},"2026-06-23","ACTUAL",{"date":93,"type":74},"2026-08-01",{"date":95,"type":74},"2034-02-01",{"name":5,"class":6},1]